CureVac rises on positive data from joint COVID and flu mRNA vaccine programs

CureVac NV

06/01/2023 13:27

** U.S.-listed shares of German vaccine developer CureVac
 CVAC.O  rise ~10% premarket to $7.04
    ** Co says COVID-19 and flu vaccine candidates using a
modified second-generation mRNA backbone showed promising
immuno­genicity and reactogenicity profiles in a joint study
    ** COVID-19 program CV0501 shown to be generally well
tolerated
    ** CV0501, which encodes Omicron variant BA.1, successfully
boosted antibody titers against BA.1
    ** Flu vaccine Flu-SV-mRNA successfully boosted antibody
titers against matching flu strain even at lowest dose and was
well tolerated across all tested dose groups
    ** Co is developing these vaccines in collaboration with
London-listed drugmaker GlaxoSmithKline  GSK.L   
    ** Stock fell ~83% last year
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))